Alexion Pharma (ALXN): Products Unimpaired - Leerink
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Netflix (NFLX) Tops Q1 EPS by 77c, Offers Guidance
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
Alexion Pharmaceuticals (ALXN) Stock Approaching 'Worst-Case' Scenario - Leerink
November 14, 2016 8:11 AM ESTLeerink Partners analyst Geoffrey Porges weighed in on Alexion Pharmaceuticals (NASDAQ: ALXN) following the sell-off on 10-Q delay. The firm said the stock is approaching worst-case downside scenarios that can only be justified if one assumes the failure of pipeline indications and of any future Soliris label expansion. They believe the stock can recover to ~$150/share.
Porges commented, "Compared to peer large-cap high growth biotechs such as... More
FBR Remains Neutral on Alexion Pharma (ALXN); Sees Sales of Kanuma Continuing to Lag
November 11, 2016 1:39 PM ESTFBR & Co. affirms Alexion Pharmaceuticals (Nasdaq: ALXN) at Market Perform with a price target of $130 after the company announced that researchers presented new longer-term data from an ongoing, open-label extension of the pivotal Phase 3 ARISE trial of Kanuma (sebelipase alfa) in children and adults with lysosomal acid lipase deficiency (LAL-D).
The... More
